Unknown

Dataset Information

Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.


ABSTRACT:

Background

Anti-CD20 B-cell depletion has not shown superior efficacy to standard immunosuppression in patients with systemic lupus erythematosus (SLE). Besides trial design, potential explanations are incomplete B-cell depletion in relation to substantial surges in B-cell-activating factor (BAFF). To improve B-cell targeting strategies, we conducted the first study in SLE patients aimed at investigating immunological effects and feasibility of combining rituximab (RTX; anti-CD20) and belimumab (BLM; anti-BAFF).

Methods

Reported is the long-term follow-up of a Phase 2 proof-of-concept study in 15 patients with SLE including 12 (80%) with lupus nephritis (LN).

Results

In 10/15 (67%) patients, a clinical response was observed by achievement of lupus low disease activity

SUBMITTER: Kraaij T 

PROVIDER: S-EPMC8311580 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature